• 한국임상약학회지
• /
• 제30권4호
• /
• pp.259-263
• /
• 2020

Background: Dual-type calcium channel blockers (CCBs), such as efonidipine and cilnidipine, are renoprotective drugs that reportedly reduce proteinuria by dilating afferent and efferent arterioles of the glomerulus. However, studies comparing the effect of dual-type CCB on proteinuria have not been conducted. Therefore, we aimed to compare the effect of dual-type CCB (efonidipine and cilnidipine) usage patterns in hypertensive patients with chronic kidney disease (CKD). Methods: This single-center, retrospective study included 53 patients with CKD who 1) initiated efonidipine or cilnidipine treatment while on a renin-angiotensin system inhibitor and 2) had received efonidipine or cilnidipine for at least one year. We compared usage patterns between the efonidipine and cilnidipine groups during the one-year period and analyzed the following outcomes: urinary protein-to-creatinine ratio, blood pressure, and serum creatinine. Results: The study included 25 patients in the efonidipine group and 28 patients in the cilnidipine group. In both groups, blood pressure and urinary protein-to-creatinine ratios tended to decrease; however, the change during each interval was not significant. Conclusions: In patients with CKD who were on renin-angiotensin system inhibitor therapy, the addition of a dual-type CCB (i.e., efonidipine or cilnidipine) tended to reduce proteinuria; however, the change during each interval was not significant.

• Childhood Kidney Diseases
• /
• 제27권2호
• /
• pp.121-126
• /
• 2023

The administration of angiotensin type 2 receptor blockers (ARBs) during pregnancy is known to cause ARB fetopathy, including renal insufficiency. We aimed to analyze the outcomes of two patients who survived ARB fetopathy and perform an accompanying literature review. Case 1 was exposed antenatally from a gestational age of 30 weeks to valsartan because of maternal pregnancy-induced hypertension. The patient presented with oliguria immediately after birth, and renal replacement therapy was administered for 24 days. Seven years after birth, renal function was indicative of stage 2 chronic kidney disease (CKD) with impaired urinary concentration. Case 2 had a maternal history of hypertension and transient ischemic attack and was treated with olmesartan until 30 weeks of pregnancy. Renal replacement therapy was performed for 4 days since birth. After 8 years, the patient is with CKD stage 2, with intact tubular function. Recent reports suggest that ARB fetopathy might manifest as renal tubular dysgenesis and nephrogenic diabetes insipidus, in contrast to mild alterations of glomerular filtration. Tubular dysfunction may induce CKD progression and growth retardation. Patients with ARB fetopathy should be monitored until adulthood. The ARB exposure period might be a critical factor in determining the severity and manifestations of fetopathy.

• 핵의학기술
• /
• 제25권2호
• /
• pp.35-40
• /
• 2021

신사구체여과율(glomerular filtration rate, GFR)은 신장 질환의 진단, 치료 및 추적 관찰에 중요한 지표이며, 건강인에서도 약제사용, 신장이식 공여자의 신장 평가 등에 사용된다. GFR 검사의 표준방법은 외인성 표지자인 이눌린(inulin)을 연속 주입하여 측정하는 방법이나, 시간이 많이 소요되고 검사 방법이 복잡하기 때문에, 혈청 크레아티닌 농도로 계산한 추정사구체여과율(estimated glomerular filtration rate, eGFR)을 대신 사용한다. 그러나 크레아티닌은 연령, 성별, 근육량 등에 영향을 받는 것으로 알려져 있으며, 현재 많이 사용되는 추정사구체여과율 공식에는 성인의 경우 Cockroft-Gault 공식, Modification of Diet in Renal Disease(MDRD) 공식, Chronic kidney Disease Epidemiology Collaboration (CKD-EPI) 공식 등이 있고, 소아의 경우 Schwartz 공식을 사용하고 있다. ^99mTC diethylenetriaminepentaacetic acid(^99mTc-DTPA)를 사용한 신사구체여과율(glomerular filtration rate, GFR) 측정은 이눌린을 대체 할 수 있어 현재 사용되고 있다. 이에 ^99mTc-DTPA를 이용하여 측정한 신사구체 여과율과 CKD-EPI 공식을 이용한 추정사구체여과율을 비교하여 보았다. 서울 아산병원을 내원한 신장이식 공여자 200명(남성 96명, 여성 104명, 47.3세±12.7)을 대상으로 ^99mTc-DTPA(0.5 mCi, 18.5 MBq)를 정맥투여 하고 획득된 plasma(Two-plasma-sample-method, TPSM)를 계측하여 신사구체여과율(glomerular filtration rate, GFR)을 측정하였다. 혈청 크레아티닌 농도를 근거로 chronic kidney disease epidemiology collaboration (CKD-EPI) 공식을 이용하여, 추정사구체여과율(estimated glomerular filtration rate, eGFR)을 도출하였다. 신장이식 공여자 200명(남성 96명, 여성 104명, 47.3세±12.7)을 대상으로 ^99mTc-DTPA를 사용하여 측정된 신사구체여과율 평균값은 97.27±19.46 (GFR, ml/min/1.73m²)이고 CKD-EPI 공식을 이용한 추정사구체여과율 (estimated glomerular filtration rate, eGFR) 평균값은 96.84±17.74(CKD-EPI, ml/min/1.73m²), 혈청 크레아타닌의 농도는 0.84±0.39 (mg/dL)이다. 혈청 크레아티닌 근거 추정사구체여과율에 대한 ^99mTc-DTPA 신사구체여과율의 회귀식은 Y= 0.5073X + 48.186, 상관계수는 0.698이었다.(P<0.01)혈청 크레아티닌 근거 추정사구체여과율에 대한 ^99mTc-DTPA 신사구체여과율의 Difference(%)는 1.52±18.28 이었다. ^99mTC-DTPA를 이용해서 측정된 신사구체여과율과 혈청 크레아티닌 농도에 기반하여 도출된 추정사구체여과율에 대한 상관계수는 0.698로 중등도 정도의 상관성을 확인할 수 있었다. 이는 추정사구체여과율은 연령, 성별, 근육 양 등 신장 외적인 요소에 영향을 받고 신장질환자를 대상으로 만든 공식을 사용하는 원인에 기인하는 것으로 추정된다. 신장 질환의 진단, 치료 및 추적 관찰, 신장이식 공여자의 신장 평가 등에 사용되는 신사구체여과율 측정에 ^99mTc-DTPA를 사용함으로써 신뢰성 있는 결과를 임상에 제공할 수 있다.

• Nutrition Research and Practice
• /
• 제16권2호
• /
• pp.147-160
• /
• 2022

BACKGROUND/OBJECTIVES: Patients with chronic kidney disease (CKD) have a high concentration of uremic toxins in their blood and often experience muscle atrophy. Indoxyl sulfate (IS) is a uremic toxin produced by tryptophan metabolism. Although an elevated IS level may induce muscle dysfunction, the effect of IS on physiological concentration has not been elucidated. Additionally, the effects of ursolic acid (UA) on muscle hypertrophy have been reported in healthy models; however, it is unclear whether UA ameliorates muscle dysfunction associated with chronic diseases, such as CKD. Thus, this study aimed to investigate whether UA can improve the IS-induced impairment of mitochondrial biogenesis. MATERIALS/METHODS: C2C12 cells were incubated with or without IS (0.1 mM) and UA (1 or 2 μM) to elucidate the physiological effect of UA on CKD-related mitochondrial dysfunction and its related mechanisms using real-time reverse transcription-polymerase chain reaction, western blotting and enzyme-linked immunosorbent assay. RESULTS: IS suppressed the expression of differentiation marker genes without decreasing cell viability. IS decreased the mitochondrial DNA copy number and ATP levels by downregulating the genes pertaining to mitochondrial biogenesis (Ppargc1a, Nrf1, Tfam, Sirt1, and Mef2c), fusion (Mfn1 and Mfn2), oxidative phosphorylation (Cycs and Atp5b), and fatty acid oxidation (Pdk4, Acadm, Cpt1b, and Cd36). Furthermore, IS increased the intracellular mRNA and secretory protein levels of interleukin (IL)-6. Finally, UA ameliorated the IS-induced impairment in C2C12 cells. CONCLUSIONS: Our results indicated that UA improves the IS-induced impairment of mitochondrial biogenesis by affecting differentiation, ATP levels, and IL-6 secretion in C2C12 cells. Therefore, UA could be a novel therapeutic agent for CKD-induced muscle dysfunction.

• 말소리와 음성과학
• /
• 제14권4호
• /
• pp.45-56
• /
• 2022

본 논문은 만성콩팥병 환자의 음성을 사용하여 질병을 자동으로 진단하고 중증도를 예측하는 최적의 방법론을 제안한다. 만성콩팥병 환자는 호흡계 근력의 약화와 성대 부종 등으로 인해 음성이 변화하게 된다. 만성콩팥병 환자의 음성을 음성학적으로 분석한 선행 연구는 존재했으나, 환자의 음성을 분류하는 연구는 진행된 바가 없다. 본 논문에서는 모음연장발화, 유성음 문장 발화, 일반 문장 발화의 발화 목록과, 수제 특징 집합, eGeMAPS, CNN 추출 특징의 특징 집합, SVM, XGBoost의 머신러닝 분류기를 사용하여 만성콩팥병 환자의 음성을 분류하였다. 총 3시간 26분 25초 분량의 1,523개 발화가 실험에 사용되었다. 그 결과, 질병을 자동으로 진단하는 데에는 0.93, 중증도를 예측하는 3분류 문제에서는 0.89, 5분류 문제에서는 0.84의 F1-score가 나타났고, 모든 과제에서 일반 문장 발화, 수제 특징 집합, XGBoost의 조합을 사용했을 때 가장 높은 성능이 나타났다. 이는 만성콩팥병 음성 자동 분류에는 화자의 발화 특성을 모두 반영할 수 있는 일반 문장 발화와 거기로부터 추출한 적절한 특징 집합이 효과적임을 시사한다.

• 한국임상수의학회지
• /
• 제40권6호
• /
• pp.399-407
• /
• 2023

Chronic kidney disease (CKD) occurs in more than 15% of the dogs over 10 years of age and causes irreversible renal function deterioration. Therefore, it is important to diagnose CKD early and treat the disease properly. The purpose of this study aimed to to evaluate the clinical utility of urine albumin/creatinine ratio (ACR) using POC (point-of-care) device as an early detection urinary biomarker in CKD dogs and to confirm the correlation between ACR and other known CKD biomarkers. Urine and serum samples were obtained from 50 healthy dogs and 50 dogs with CKD. Serum blood urea nitrogen (BUN), creatinine, and symmetric dimethylarginine (SDMA) concentrations, and urine protein creatinine ratio (UPC) were measured. Urine specific gravity (USG) was evaluated using refractometer, and ACR was measured using an i-SENS A1Care analyzer. The ACR values of dogs with CKD were significantly different from those of healthy dogs (p < 0.001), as with other renal biomarkers. ACR showed significant differences between healthy dogs and dogs with CKD at every IRIS stage (p < 0.005), whereas no significant differences were observed between dogs with CKD IRIS stage I and healthy dogs with UPC. There are significant positive correlation between ACR and BUN (r = 0.611, p < 0.001), creatinine (r = 0.788, p < 0.001), SDMA (r = 0.747, p < 0.001), and UPC (r = 0.784, p < 0.001), and significant negative correlation between ACR and USG (r = -0.700, p < 0.001). In receiver operator characteristic curve analysis, the area under the curve (AUC) was 0.982 (95% CI 0.963-1.000, p < 0.001), with an optimal cut-off value of 64.20 mg/g (94% sensitivity and 94% specificity). Thus, ACR is a useful urinary biomarker for the early diagnosis of proteinuria in CKD and combined use of ACR and other renal biomarkers may be helpful for early diagnosis and prevention of CKD in dogs.

• Childhood Kidney Diseases
• /
• 제27권2호
• /
• pp.70-75
• /
• 2023

Dent disease is a rare inherited kidney tubulopathy caused by mutations in either the CLCN5 (Dent disease 1) or OCRL1 (Dent disease 2) genes, and which is often underdiagnosed in practice. A diagnosis is clinically suspected in patients with low-molecular-weight proteinuria, hypercalciuria, and one of the following: hematuria, nephrolithiasis, nephrocalcinosis, hypophosphatemia, or chronic kidney disease. Inheritance is X-linked recessive, meaning, these symptoms are generally only found in males; female carriers may have mild phenotypes. Genetic testing is only a method to confirm the diagnosis, approximately 25% to 35% of patients have neither the CLCN5 nor OCRL1 pathogenic variants (Dent disease 3), making diagnosis more challenging. The genotype-phenotype correlations are not evident with the limited clinical data available. As with many other genetic diseases, the management of patients with Dent disease concentrates on symptom relief rather than any causative process. The current treatments are mainly supportive to reduce hypercalciuria and prevent nephrolithiasis. Chronic kidney disease progresses to end-stage between the ages of the third to fifth decades in 30% to 80% of affected males. In this review, we aimed to summarize the literature on Dent disease and reveal the clinical characteristics and molecular basis of Korean patients with Dent disease.

• 대한한방내과학회지
• /
• 제42권5호
• /
• pp.727-737
• /
• 2021

Objectives: This study investigated the effect of Korean medicine on an elderly patient with posterior circulation cerebral infarction, chronic kidney disease (CKD), and early neurological deterioration (END). Methods: The patient, who already had CKD, was treated with Korean medicine, comprising herbal medicine, acupuncture, moxa, and cupping combined with Western medicine (antiplatelet, diabetes) and physical therapy. A manual muscle test (MMT) and a modified Barthel index (MBI) were used to observe the treatment effects, and blood tests were performed to check estimated glomerular filtration rate (eGFR), creatinine and blood urea nitrogen (BUN), which represent renal function. Results: After the treatment, MMT, MBI, and renal function scores had increased. Conclusions: This study suggests that Korean medicine can effectively treat posterior circulation cerebral infarction with END in CKD, but further studies should be conducted.

• 한국임상수의학회지
• /
• 제27권6호
• /
• pp.723-725
• /
• 2010

14년령의 잡종 암컷 고양이가 다식증, 과잉행동 및 체중감소를 주증으로 내원 하였다. 신체검사에서 빈맥과 고혈압이 확인되었으며, 실험실 검사를 통하여 요소 질소 증 및 갑상선 호르몬 (TT4, fT4)의 상승이 확인 되었다. 환자는 확진을 위하여 T3 억압 시험이 시행 되었으며, 검사 결과 외부에서 T3가 공급된 전후의 갑상선 호르몬 수치에 변화가 없는 것이 확인 되었다. 따라서, 환축은 만성 신부전에 병발한 갑상선 기능 항진증으로 진단되었으며, 메티마졸을 이용한 약물 관리가 실시 되었다. 결론적으로 본 증례의 경우 고양이에서 발생한 만성 신부전에 병발한 갑상선 기능 항진증의 임상증상과 진단, 그리고 치료 반응에 대한 국내 첫 증례보고이다.

• Childhood Kidney Diseases
• /
• 제27권1호
• /
• pp.19-25
• /
• 2023

Proteinuria is an important risk factor for renal and cardiovascular disease. It is associated with a risk for glomerulonephritis, chronic kidney disease, and end-stage renal disease. Therefore, if persistent proteinuria is detected, kidney biopsy is considered to diagnose and treat the underlying disease. Recently, variants in the cubilin (CUBN) gene, which is associated with albuminuria, have been reported. This gene encodes cubilin, a membrane glycoprotein receptor expressed in the renal proximal tubules. Cubilin is a component of the megalin and cubilin-amnionless complex that mediates albumin reabsorption into the proximal tubules through endocytosis. A defect in cubilin leads to a reduction in albumin reuptake, resulting in albumin-dominant proteinuria. Although numerous controversies exist, several reports suggest that cubilin defects lead to proteinuria with a high portion of albuminuria but may not impair renal filtration function. If albuminuria due to reduced cubilin function is confirmed as a benign condition, we can consider using genetic studies to detect CUBN mutations in patients with proteinuria and they may not require any treatment or kidney biopsy. Here, we review recent papers on CUBN mutations and discuss the prognosis and management of individuals with this mutation.